Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $26

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $24 to $26.
byBenzinga Newsdesk
March 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $24 to $26.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0